MARKET

CLYM

CLYM

Climb Bio
NASDAQ
5.44
+0.79
+16.99%
After Hours: 5.31 -0.13 -2.39% 19:46 02/06 EST
OPEN
4.720
PREV CLOSE
4.650
HIGH
5.45
LOW
4.698
VOLUME
893.70K
TURNOVER
--
52 WEEK HIGH
5.60
52 WEEK LOW
1.050
MARKET CAP
370.92M
P/E (TTM)
-7.2475
1D
5D
1M
3M
1Y
5Y
1D
Climb Bio Inc. to Participate in Major Healthcare Investor Conferences
Reuters · 2d ago
Weekly Report: what happened at CLYM last week (0126-0130)?
Weekly Report · 5d ago
Weekly Report: what happened at CLYM last week (0119-0123)?
Weekly Report · 01/26 09:48
Ten new option listings and two option delistings on January 22nd
TipRanks · 01/22 13:36
Weekly Report: what happened at CLYM last week (0112-0116)?
Weekly Report · 01/19 09:52
Analysts Are Bullish on Top Healthcare Stocks: Climb Bio (CLYM), Travere Therapeutics (TVTX)
TipRanks · 01/14 00:10
Weekly Report: what happened at CLYM last week (0105-0109)?
Weekly Report · 01/12 09:51
Climb Bio’s CLYM116 Moves Into First-in-Human Testing: What Early Investors Should Watch
TipRanks · 01/09 16:32
More
About CLYM
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).

Webull offers Climb Bio Inc stock information, including NASDAQ: CLYM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLYM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLYM stock methods without spending real money on the virtual paper trading platform.